CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
+$0.10 today
- Market cap
- $257.29M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
Volume 0.19M
Average 0.10M
CAMP Debt Repayment
Cash used to repay borrowings during the period.
CAMP4 Therapeutics CorporationNASDAQ: CAMP
Debt Repayment · Q1 FY2026 · quarter ended Mar 2026
Debt repayment turns positive
Q1 FY2026 debt repayment was $0, compared with -$151K a year earlier. Trailing-twelve-month debt repayment was $40K.
Context
- Debt repayment amounted to 5.9% of revenue in FY2025, down 120.4 pp from a year earlier.
- Debt repayment increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $10K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- (208K) USD
- Year-over-year change
- +74.8%
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (208K) | +74.8% |
| FY2024 | 2024-12-31 | (824K) | -810.3% |
| FY2023 | 2023-12-31 | 116K | +224.7% |
| FY2022 | 2023-02-28 | (93K) | — |
| FY2021 | 2022-02-28 | — | — |
Debt Repayment vs competitors
How CAMP compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +105.2% is the 2nd highest of 4, against a peer median of +8.5%.
- Debt repayment amounts to 1.0% of revenue for CAMP, versus a peer median of 5.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $2.67M USD | +178.3% | — | — | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$961K CAD | -134.3% | — | 5.2% |
| LTM Mar 2026 | $550K USD | +8.5% | +101.4% | 289.5% | |
| LTM Mar 2026 | $40K USD | +105.2% | — | 1.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $0 USD | — | — | — |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding CAMP) | — | +8.5% | +101.4% | 5.2% | |
Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.99M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 1.38M | 2.91M | 4.03M | 4M |
| Change in Working Capital | 1.59M | 373K | (154K) | (1.88M) | 13.01M |
| Accounts Receivables | 1.44M | 0 | 0 | 0 | 0 |
| Inventory | 5.16M | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (1.03M) |
| Other Working Capital | (5.01M) | 373K | (154K) | (1.88M) | 14.04M |
| Other Non-Cash Items | (11.94M) | 3.02M | 705K | 2.39M | 32.21M |
| Operating Cash Flow | (4.22M) | (38.54M) | (44.16M) | (45.56M) | (29.55M) |
| Capital Expenditures | (13.3M) | (4.03M) | (678K) | (441K) | (279K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 36K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 5.72M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7.58M) | (4.03M) | (678K) | (441K) | (243K) |
| Debt Repayment | — | (93K) | 116K | (824K) | (208K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.64M) | 100.25M | 185K | 72.49M | 14.93M |
| Financing Cash Flow | (2.64M) | 100.16M | 301K | 71.66M | 75.89M |
| Effect of Forex Changes | (965K) | 25.6M | 0 | 0 | 0 |
| Net Change in Cash | (15.4M) | 83.19M | (44.53M) | 25.66M | 46.09M |
| Free Cash Flow | (17.52M) | (42.57M) | (44.83M) | (46M) | (29.83M) |
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
Intrinsic Alpha fair value
Locked
Current Price
$4.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.